Consensus statement: medical management of acromegaly.

In November 2003, the Pituitary Society and the European Neuroendocrine Association sponsored a consensus workshop in Seville to address challenging issues in the medical management of acromegaly. Participants comprised 70 endocrinologists and neurosurgeons with international expertise in managing patients with acromegaly. All participants participated in the workshop proceedings, and the final document written by the scientific committee reflects the consensus opinion of the interactive deliberations. The meeting was supported by an unrestricted educational grant from Ipsen. No pharmaceutical representatives participated in the program planning or in the scientific deliberations.

[1]  P. Chanson,et al.  Diagnosis and treatment of acromegaly complications , 2003, Journal of endocrinological investigation.

[2]  G. Lasio,et al.  Four-year treatment with octreotide-long-acting repeatable in 110 acromegalic patients: predictive value of short-term results? , 2003, The Journal of clinical endocrinology and metabolism.

[3]  P. Chanson,et al.  Guidelines for acromegaly management. , 2002, The Journal of clinical endocrinology and metabolism.

[4]  P. Trainer.  Acromegaly—Consensus, What Consensus? , 2002 .

[5]  F. Di Salle,et al.  Long‐term effects of lanreotide SR and octreotide LAR® on tumour shrinkage and GH hypersecretion in patients with previously untreated acromegaly , 2002, Clinical endocrinology.

[6]  P. Trainer.  Editorial: acromegaly--consensus, what consensus? , 2002, The Journal of clinical endocrinology and metabolism.

[7]  Andrea Giustina,et al.  Differential Inhibition of Growth Hormone Secretion by Analogs Selective for Somatostatin Receptor Subtypes 2 and 5 in Human Growth-Hormone-Secreting Adenoma Cells in vitro , 2001, Neuroendocrinology.

[8]  M. S. Tewart,et al.  Treatment of acromegaly with the growth hormone-receptor antagonist pegvisomant. , 2000 .

[9]  F. Casanueva,et al.  Criteria for cure of acromegaly: a consensus statement. , 2000, The Journal of clinical endocrinology and metabolism.

[10]  J. A. Scarlett,et al.  Treatment of acromegaly with the growth hormone-receptor antagonist pegvisomant. , 2000, The New England journal of medicine.